Synlogic 2024 Q1 Earnings Widened Net Loss of $25.61M -63.9% YoY Amid Revenue Drop

Synlogic (SYBX) reported fiscal 2024 Q1 earnings on Nov 14, 2025, with results showing a 95.4% revenue decline to $8M and a 63.9% increase in net loss to -$25.61M. The company has sustained losses for seven consecutive years, underscoring persistent financial challenges. While the per-share loss improved by 37.8%, the overall performance highlights structural vulnerabilities.

Synlogic’s Q1 revenue plummeted to $8,000 from $174,000 in 2023 Q1, a 95.4% year-over-year contraction. The sharp decline reflects ongoing operational headwinds and unmet business objectives in the microbiome therapeutics sector.

Earnings/Net Income

The company narrowed its per-share loss to -$2.11 from -$3.39, a 37.8% improvement, but the net loss expanded to -$25.61M, up 63.9% from -$15.62M in 2023 Q1. Sustained losses over seven years and volatile financial metrics—such as -28.53% return on equity—underscore the risks of investing in Synlogic.

Post-Earnings Price Action Review

The strategy of buying Synlogic shares post-earnings and holding for 30 days showed mixed results over three years. While it outperformed the S&P 500 in 2024 and 2025 (166.86% and 236.38%, respectively), quarterly volatility—such as a 0.00% return in one quarter—highlighted unpredictability. Success hinged on revenue trends: stable quarter-over-quarter revenue signaled potential growth, but high volatility metrics (196.27 price-to-book ratio) reflected market uncertainty. Investors must weigh these risks against the strategy’s long-term potential.

CEO Commentary

CEO emphasized advancing microbiome therapeutics for rare diseases, noting manufacturing scaling and regulatory hurdles as key challenges. Strategic priorities include accelerating pipeline trials and partnerships, with cautious optimism for long-term growth despite current R&D-driven losses.

Guidance

Synlogic did not provide quantitative 2024 Q1 guidance, disclosing actual results (revenue: $8.0M, EPS: -$2.11). The CEO reiterated disciplined capital allocation and clinical advancements but omitted specific financial targets.

Additional News

No significant non-earnings-related news for Synlogic emerged within three weeks of Nov 14, 2025. The company remained focused on clinical development without notable M&A, leadership changes, or dividend announcements. Market attention stayed centered on its microbiome pipeline and operational efficiency efforts.